The drug was shown in clinical trials to reduce the progression of Alzheimer’s disease by 27 per cent. That means patients who received the treatment as part of the double blind study experienced a slowing of their disease progression. They did continue to get worse, but at a slower rate than most of those not on the treatment. The treatment comes with a small, but serious, risk of brain bleeds and brain swelling.
